The EU Council's Working Party on Pharmaceuticals and Medical Devices is scheduled to hold a meeting on 3-4 September 2026 to exchange views on the proposed European Biotech Act, according to a notice of meeting and provisional agenda published on 23 July 2026. The Act aims to strengthen the EU's biotechnology and biomanufacturing sectors, particularly in health, by establishing a framework of measures and amending several existing regulations.
The meeting will focus on the Commission's proposal, which seeks to enhance innovation, supply security, and competitiveness in biotech and biomanufacturing within the healthcare sector. The Act would amend Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795, and (EU) 2024/1938, covering areas from food safety to advanced therapies and veterinary medicines.
Policy orientations and trade-offs The proposed Act represents a push to streamline regulatory processes for biotech and biopharmaceutical products, potentially accelerating market access for advanced therapies and medical devices. However, amendments to existing frameworks may require national authorities and industry to adapt to new rules, creating a trade-off between faster innovation and regulatory stability. The Act also aims to bolster the EU's strategic autonomy and crisis preparedness in health biotechnologies, which could reduce dependence on non-EU suppliers but may impose new compliance costs on producers.
Impact on stakeholders - EU biotech and pharmaceutical companies: Could benefit from simplified approval pathways and increased competitiveness, but may face transitional costs to align with amended regulations. - National regulatory authorities: Would need to implement changes to oversight procedures, potentially requiring additional resources and training. - Healthcare providers and patients: May gain earlier access to innovative therapies, though safety and efficacy standards must be maintained. - EU taxpayers and public health systems: Could see improved crisis preparedness and supply security, but public funding may be needed to support biomanufacturing infrastructure.
Institutional follow-up The Working Party's exchange of views will feed into the Council's deliberations on the proposal. The European Parliament is expected to examine the Act in parallel, with co-decision procedures likely to follow. The meeting on 3-4 September will be a key step in shaping the Council's position before negotiations with the Parliament and Commission.